Delivery Order SPE2DB24D9222-SPE2DB25FAZJB
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $7,955.39 by the Defense Logistics Agency on July 23, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, with an ultimate completion date of July 24, 2025, was issued without a set-aside designation, allowing the vendor to compete on an unrestricted basis. The award represents a continuation...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency on April 23, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, which is scheduled for completion by April 24, 2025, was issued without a set-aside designation. The award represents a continuation of DMS Pharmaceutical Group's substantial role as a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency on July 14, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, which is expected to be completed by July 15, 2025, represents a discrete fulfillment under the company's larger Indefinite Delivery Contract with DLA. The award carries no set-aside...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,622.72 by the Defense Logistics Agency on August 25, 2025, for the supply of Xtandi 40 mg capsules (120-count). The contract carries no set-aside designation and is scheduled for completion by August 26, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 28, 2025, valued at $4,169.59 for the supply of Xtandi 40 mg tablets (120 count) to the Defense Logistics Agency (DLA). This firm fixed-price delivery order, which must be completed by July 29, 2025, carries no set-aside designation. The award leverages DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,622.72 by the Defense Logistics Agency on July 29, 2025. The contract calls for the delivery of Xtandi 40 mg capsules (120-count units) with an ultimate completion date of July 30, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete directly in the federal...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of July 25, 2025, and carries no set-aside designation. This award was issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count). The contract is structured as a firm fixed-price delivery order with an ultimate completion date of July 22, 2025, and carries no set-aside designation. The place of performance is located in Park Ridge, Illinois, where the vendor...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Xtandi 80 mg tablets (60-count units) with a ceiling value of $4,169.59. This delivery order, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on July 22, 2025, for 60 tablets of Xtandi 80 mg, a prescription medication commonly used in oncology treatment. The delivery order, valued at $4,169.59 with firm fixed pricing, is expected to be completed by July 23, 2025. This award carries no set-aside designation and represents a direct distribution of...
- SPE2DB24D9222Indefinite Delivery Contract
- SPE2DB24D9222-SPE2DB25FAZJBDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $25,017.54 by the Defense Logistics Agency on June 18, 2025, for the supply of Xtandi 40 mg tablets (120-count units). The award utilizes a firm fixed-price contract structure with no set-aside designation, and is scheduled for ultimate completion by June 20, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, which carries a total potential value of $499,999,999 and remains valid through November 2026. The Defense Logistics Agency issues delivery orders through the SPE2DB program to ensure pharmaceutical supply continuity for Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's role as a critical pharmaceutical distributor under this framework includes providing branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to military health facilities. The current award for Xtandi—an oncology treatment medication—reflects the contractor's established capacity to deliver specialized pharmaceutical products supporting the medical supply needs of the federal healthcare system on an expedited basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.0k | 6/18/25 |